Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients (MARMEFE)

Ramsay Générale de Santé

Status: Enrolling

Conditions: Hemodialysis Complication; Hepatic Metabolic Disorders; Calcium Phosphate Metabolism; Iron Metabolism Disorders

Treatments: Procedure: Blood test

Study type: Observational

Funder types: Other

Identifiers

NCT05586867

2021-A01329-32

Details and patient eligibility

About

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure.

The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients.

The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult dialysis patient
• Patient able to understand the information necessary for the study and having signed his written consent to participate
• Affiliated patient or beneficiary of a social security scheme.

Exclusion criteria

• Medically unstable or frail patient
• Patient with hemoglobin less than 7g/dl
• Patient with HIV+ or AIDS, patient with replicating hepatitis B or C
• Patient participating in another clinical study requiring an additional blood sample
• Patient benefiting from legal protection measures (guardianship, guardianship, etc.) adult under guardianship, guardianship or other legal protection, deprived of freedom by judicial or administrative decision
• Pregnant, breastfeeding or parturient woman

Trial design

200 participants in 1 patient group

Hemodialysis patient

Treatment:

Procedure: Blood test